[1] MELISSA R PITMAN. The sphingosine 1-phosphate receptor 2/4 antagonist JTE-013 elicits off-target effects on sphingolipid metabolism.[J]. Scientific Reports, 2022: 454. DOI:
10.1038/s41598-021-04009-w[2] MAKOTO OSADA. Enhancement of sphingosine 1-phosphate-induced migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist[J]. Biochemical and biophysical research communications, 2002, 299 3: Pages 483-487. DOI:
10.1016/s0006-291x(02)02671-2[3] KAYO ARIKAWA. Ligand-dependent inhibition of B16 melanoma cell migration and invasion via endogenous S1P2 G protein-coupled receptor. Requirement of inhibition of cellular RAC activity.[J]. The Journal of Biological Chemistry, 2003, 278 35: 32841-32851. DOI:
10.1074/jbc.m305024200[4] QIUMIN XU BMED . JTE-013 Alleviates Inflammatory Injury and Endothelial Dysfunction Induced by Sepsis In Vivo and In Vitro[J]. Journal of Surgical Research, 2021, 265: Pages 323-332. DOI:
10.1016/j.jss.2021.03.006[5] MENGDIE WANG. Inhibition of sphingosine 1-phosphate (S1P) receptor 1/2/3 ameliorates biological dysfunction in rheumatoid arthritis fibroblast-like synoviocyte MH7A cells through Gαi/Gαs rebalancing[J]. Clinical and Experimental Pharmacology and Physiology, 2021, 48 8: 1080-1089. DOI:
10.1111/1440-1681.13460[6] STEPHANIE S DUSABAN. Sphingosine 1-phosphate receptor 3 and RhoA signaling mediate inflammatory gene expression in astrocytes.[J]. Journal of Neuroinflammation, 2017: 111. DOI:
10.1186/s12974-017-0882-x[7] NADINE AL ALAM Sawsan I K. FTY720P inhibits hepatic Na(+)-K(+) ATPase via S1PR2 and PGE2.[J]. Biochemistry and Cell Biology, 2016, 94 4: 371-377. DOI:
10.1139/bcb-2016-0025